Fennec Pharmaceuticals Inc. (FENC) financial statements (2022 and earlier)

Company profile

Business Address PO BOX 13628
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. BC
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,10030,34413,65022,78128,2603,926942
Cash and cash equivalents21,10030,34413,65022,78128,2603,926942
Prepaid expense1,0347972261681284376
Other current assets253276811331
Total current assets:22,38731,41713,88422,95028,4013,9721,019
Noncurrent Assets
Other undisclosed noncurrent assets27 262    
Total noncurrent assets:27 262    
TOTAL ASSETS:22,41431,41714,14622,95028,4013,9721,019
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,6542,3472,2711,6371,477369389
Accounts payable7771,5711,6121,032855244297
Accrued liabilities87777665960562212592
Derivative instruments and hedges, liabilities    1673382
Total current liabilities:1,6542,3472,2711,6371,644402471
Noncurrent Liabilities
Other undisclosed noncurrent liabilities4,988      
Total noncurrent liabilities:4,988      
Total liabilities:6,6422,3472,2711,6371,644402471
Stockholders' equity
Stockholders' equity attributable to parent15,77229,07011,87521,31326,7573,570548
Common stock140,801140,733106,392106,392103,04574,51569,153
Additional paid in capital53,21449,23448,27144,93443,83742,13441,685
Accumulated other comprehensive income1,2431,2431,2431,2431,2431,2431,243
Accumulated deficit(179,486)(162,140)(144,031)(131,256)(121,368)(114,322)(111,533)
Total stockholders' equity:15,77229,07011,87521,31326,7573,570548
TOTAL LIABILITIES AND EQUITY:22,41431,41714,14622,95028,4013,9721,019

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(17,223)(18,055)(13,009)(10,409)(6,951)(2,871)(1,890)
Other undisclosed operating income 170     
Operating loss:(17,223)(17,885)(13,009)(10,409)(6,951)(2,871)(1,890)
Nonoperating income (expense)(123)(224)234521(95)821,231
Investment income, nonoperating54873153484783
Other nonoperating income (expense) (9)(17)6(8)(14) 
Interest and debt expense (402)(64)    
Net loss:(17,346)(18,511)(12,839)(9,888)(7,046)(2,789)(659)
Other undisclosed net income attributable to parent 40264    
Net loss available to common stockholders, diluted:(17,346)(18,109)(12,775)(9,888)(7,046)(2,789)(659)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(17,346)(18,511)(12,839)(9,888)(7,046)(2,789)(659)
Comprehensive loss, net of tax, attributable to parent:(17,346)(18,511)(12,839)(9,888)(7,046)(2,789)(659)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: